Editor’s Choice
Main Category: Pregnancy / Obstetrics
Also Included In: HIV / AIDS
Article Date: 15 May 2012 – 14:00 PDT
email to a friend 
printer friendly 
opinions
<!– 
rate article
Patient / Public:
Tenofovir, the anti-HIV drug, is safe to use during pregnancy according to a new study published in PloS Medicine. The researchers, led by Diana Gibb from the MRC Clinical Trials Unit in London, UK, found that the drug does not increase the risk of kidney problems, birth defects or growth abnormalities in infants born to HIV-positive women in Africa.
The team examined data from the Development of AntiRetroviral Therapy of Africa (DART) trial in order to determine what affect Antiretroviral therapy (ART – a combination of anti-HIV drugs) had on infants born to Ugandan and Zimbabwean HIV-positive women who took ART during pregnancy.
The majority of women the team examined were taking a tenofovir-containing combination of anti-HIV drugs before and throughout their pregnancies. After comparing infants exposed and not exposed to tenofovir-containing ART during pregnancy, the researchers found that that out of the 226 live births, there was no increase in the proportion of infants who died shortly after birth (3%) or had birth defects (3%).
In a follow-up study, the team found that 14 of the 182 surviving infants died – giving a one-year mortality rate of 5%. This figure is comparable to the normal infant mortality rate in the region (2-4%), and significantly lower than infants born to severely HIV-Infected untreated mothers.
In addition, none of the surviving infants were HIV-positive, none suffered kidney problems or bone fractures during follow-up and the researchers found no effect on growth at two years.
The researchers explained:
“We observed no evidence that tenofovir versus non-tenofovir ART had any adverse effects on pregnancy outcomes or on congenital, renal, bone, or growth abnormalities up to age 4 among children born to women with severe HIV immunodeficiency at ART initiation and exposed throughout the intrauterine period.
Our findings suggest tenofovir-containing ART is a reasonable choice in pregnancy and that tenofovir pre-exposure prophylaxis is also reasonable for women who are at high risk of seroconverting during pregnancy.”
They conclude:
“Detailed safety of tenofovir for pre-exposure prophylaxis will need confirmation from longer term follow-up of larger numbers of exposed children.”
Written By Grace Rattue
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
- Additional
- References
- Citations
Please use one of the following formats to cite this article in your essay, paper or report:
MLA
APA
Please note: If no author information is provided, the source is cited instead.
Add Your Opinion On This Article
‘Tenofovir Safe For HIV-Positive Pregnant Mothers’
Please note that we publish your name, but we do not publish your email address. It is only used to let
you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care
professional. For more information, please read our terms and conditions.
//www.medilexicon.org” target=”_blank” rel=”nofollow”>
Privacy Policy |
Terms and Conditions
//www.medilexicon.org” target=”_blank”>MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
MNT (logo) is the registered EU trade mark of MediLexicon Int. Limited.
//www.everydayhealth.com” target=”_blank” rel=”nofollow”>
back to top | home |
privacy policy
//www.medilexicon.org” target=”_blank” rel=”nofollow”>
//www.medilexicon.org” target=”_blank”>MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
MNT (logo) is the registered EU trade mark of MediLexicon Int. Limited.
Article source: http://www.medicalnewstoday.com/articles/245426.php
Related posts
- Get Rid of Bed Bugs Naturally Video Series Released By...
- IMN Systems Launches New Social TV Service Called "Simul TV"...
- World Record-Setting Zumba Class, Brazilian Dignitaries and World Cup...
- Trayvon Martin: "A Tale Of Two Hoodies"
- Donegal Importers to Attend Over 50 Fairs and Festivals in the USA
- New e-Directory Promises to Become the White and Yellow Pages of the...
- Lyrica (pregabalin) No Good For Diabetes Or HIV Associated Neuropathic Pain
- New Atmospheric Monitoring System for Underground Mining that also...
- How to Avoid Dry, Cracked Lips This Winter
- Metabolism Of Certain Drugs Varies Between Genders And May Be Reflected In Anti-HIV Drug Efficacy
